Evidence map›Paper›PMID 29719438›Full record

ArticleCurrent oncology (Toronto, Ont.)2018

Adherence to, and outcomes of, a galactomannan screening protocol in high-risk hematology patients.

S Harricharan, K Biederman, A M Bombassaro, A Lazo-Langner, S Elsayed, A Fulford, J A Delport, A Xenocostas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

S HarricharanCanadian Agency for Drugs and Technologies in Health, Toronto, ON.
K BiedermanPharmacy Services, London Health Sciences Centre, London, ON.
A M BombassaroPharmacy Services, London Health Sciences Centre, London, ON.
A Lazo-LangnerDepartment of Medicine, Division of Hematology, Schulich School of Medicine and Dentistry, Western University, London, ON.
S ElsayedDepartment of Medicine, Division of Infectious Diseases, Schulich School of Medicine and Dentistry, Western University, London, ON.
A FulfordArthur Labatt Family School of Nursing, Western University, London, ON.
J A DelportDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON.
A XenocostasDepartment of Medicine, Division of Hematology, Schulich School of Medicine and Dentistry, Western University, London, ON.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A twice-weekly galactomannan (gm) screening protocol was implemented in high-risk hematology inpatients. Study objectives were to determine adherence to the protocol, use of selected resources, and patient outcomes. Methods: This retrospective cohort study compared outcomes of interest before and after implementation of gm screening. Adults undergoing matched related allogeneic hematopoietic stem-cell transplantation or induction chemotherapy for acute leukemia were eligible. Patients could be enrolled more than once and were evaluated as episodes. Adherence to the gm protocol was assessed in post-implementation episodes. Use of broad-spectrum antifungals (bsafs), consultations (infectious diseases, respirology), and diagnostic procedures (computed tomography imaging, bronchoalveolar lavage) were compared between phases, as were the patient outcomes of all-cause mortality and clinical success (alive and not taking a bsaf). Results: Of 182 episodes consecutively screened, 70 per phase were enrolled. Clinical characteristics and duration of assessment were similar for the phases. Full or partial adherence to the protocol was observed in 61 post-implementation episodes (87%), with full adherence in 40 episodes (57%). More episodes in the pre-implementation phase than in the post-implementation phase involved receipt of bsafs, consultations, and diagnostics (27% vs. 7%, Conclusions: Implementation of a gm screening protocol was feasible and associated with significantly fewer episodes involving receipt of bsafs and consultations, and with significantly more episodes showing clinical success.

Indexed as

AdultAgedAntifungal AgentsBiomarkersFeasibility StudiesFemaleGalactoseGuideline AdherenceHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLeukemiaMaleMannansMass ScreeningMiddle AgedAntifungal AgentsBiomarkersgalactomannanGalactoseMannansAdherenceantifungalsconsultationsdiagnosticsgalactomannanhematologymortalityscreening

Identifiers

PMID29719438
PMCPMC5927793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.